164 related articles for article (PubMed ID: 33051434)
1. β
Mele L; Del Vecchio V; Marampon F; Regad T; Wagner S; Mosca L; Bimonte S; Giudice A; Liccardo D; Prisco C; Schwerdtfeger M; La Noce M; Tirino V; Caraglia M; Papaccio G; Desiderio V; Barbieri A
Cell Death Dis; 2020 Oct; 11(10):850. PubMed ID: 33051434
[TBL] [Abstract][Full Text] [Related]
2. β
Del Vecchio V; Mele L; Panda SK; Sanchez-Pajares IR; Mosca L; Tirino V; Barbieri M; Bruzzese F; Luciano A; Marino FZ; Accardo M; Nicoletti GF; Papaccio G; Barbieri A; Desiderio V
Cell Death Dis; 2023 Sep; 14(9):613. PubMed ID: 37723219
[TBL] [Abstract][Full Text] [Related]
3. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor receptor 3-mediated reactivation of ERK signaling promotes head and neck squamous cancer cell insensitivity to MEK inhibition.
Ban MJ; Byeon HK; Yang YJ; An S; Kim JW; Kim JH; Kim DH; Yang J; Kee H; Koh YW
Cancer Sci; 2018 Dec; 109(12):3816-3825. PubMed ID: 30343534
[TBL] [Abstract][Full Text] [Related]
5. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
[TBL] [Abstract][Full Text] [Related]
6. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
Namani A; Matiur Rahaman M; Chen M; Tang X
BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
[TBL] [Abstract][Full Text] [Related]
7. Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
Wang Z; Goto Y; Allevato MM; Wu VH; Saddawi-Konefka R; Gilardi M; Alvarado D; Yung BS; O'Farrell A; Molinolo AA; Duvvuri U; Grandis JR; Califano JA; Cohen EEW; Gutkind JS
Nat Commun; 2021 Apr; 12(1):2383. PubMed ID: 33888713
[TBL] [Abstract][Full Text] [Related]
8. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
9. Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Michmerhuizen NL; Leonard E; Matovina C; Harris M; Herbst G; Kulkarni A; Zhai J; Jiang H; Carey TE; Brenner JC
Mol Pharmacol; 2019 May; 95(5):528-536. PubMed ID: 30858165
[TBL] [Abstract][Full Text] [Related]
10. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
[TBL] [Abstract][Full Text] [Related]
11. Bone Marrow-Derived Mesenchymal Stem Cells Promoted Cutaneous Wound Healing by Regulating Keratinocyte Migration via β
Huo J; Sun S; Geng Z; Sheng W; Chen R; Ma K; Sun X; Fu X
Mol Pharm; 2018 Jul; 15(7):2513-2527. PubMed ID: 29757659
[TBL] [Abstract][Full Text] [Related]
12. Selective β2-AR Blockage Suppresses Colorectal Cancer Growth Through Regulation of EGFR-Akt/ERK1/2 Signaling, G1-Phase Arrest, and Apoptosis.
Chin CC; Li JM; Lee KF; Huang YC; Wang KC; Lai HC; Cheng CC; Kuo YH; Shi CS
J Cell Physiol; 2016 Feb; 231(2):459-72. PubMed ID: 26189563
[TBL] [Abstract][Full Text] [Related]
13. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
[TBL] [Abstract][Full Text] [Related]
14. PDK1 Mediates
Sambandam V; Frederick MJ; Shen L; Tong P; Rao X; Peng S; Singh R; Mazumdar T; Huang C; Li Q; Pickering CR; Myers JN; Wang J; Johnson FM
Clin Cancer Res; 2019 Jun; 25(11):3329-3340. PubMed ID: 30770351
[TBL] [Abstract][Full Text] [Related]
15. Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines.
Stegeman H; Kaanders JH; Verheijen MM; Peeters WJ; Wheeler DL; Iida M; Grénman R; van der Kogel AJ; Span PN; Bussink J
Mol Cancer; 2013 Nov; 12(1):133. PubMed ID: 24192080
[TBL] [Abstract][Full Text] [Related]
16. Potential inhibitors of RPS6KB2 and NRF2 in head and neck squamous cell carcinoma.
Madhukar G; Subbarao N
J Biomol Struct Dyn; 2024; 42(4):1875-1900. PubMed ID: 37160694
[TBL] [Abstract][Full Text] [Related]
17. Dissociation of β1- and β2-adrenergic receptor subtypes in the retrieval of cocaine-associated memory.
Fitzgerald MK; Otis JM; Mueller D
Behav Brain Res; 2016 Jan; 296():94-99. PubMed ID: 26318933
[TBL] [Abstract][Full Text] [Related]
18. Schedule-dependent interaction between temsirolimus and cetuximab in head and neck cancer: a preclinical study.
Lattanzio L; Milano G; Monteverde M; Tonissi F; Vivenza D; Merlano M; Lo Nigro C
Anticancer Drugs; 2016 Jul; 27(6):533-9. PubMed ID: 26982238
[TBL] [Abstract][Full Text] [Related]
19. Pairing a prognostic target with potential therapeutic strategy for head and neck cancer.
Lek SM; Li K; Tan QX; Shannon NB; Ng WH; Hendrikson J; Tan JWS; Lim HJ; Chen Y; Koh KKN; Skanthakumar T; Kwang XL; Chong FT; Leong HS; Tay G; Putri NE; Lim TKH; Hwang JSG; Ang MK; Tan DSW; Tan NC; Tan HK; Kon OL; Soo KC; Iyer NG; Ong CJ
Oral Oncol; 2020 Dec; 111():105035. PubMed ID: 33091845
[TBL] [Abstract][Full Text] [Related]
20. A molecular signature of well-differentiated oral squamous cell carcinoma reveals a resistance mechanism to metronomic chemotherapy and novel therapeutic candidates.
Kina S; Kawabata-Iwakawa R; Miyamoto S; Arasaki A; Sunakawa H; Kinjo T
J Drug Target; 2021 Dec; 29(10):1118-1127. PubMed ID: 33979258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]